Merontos, Menzl Mae V.
HRN: 13 21 16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/30/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/30/2023
06/06/2023
IV
500mg
Q6hrs
Intestinal Amoebiasis
Waiting Final Action
Indication: Empirical Escalation Type of Infection: Intra-abdominalFebrile Neutropenia Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes